《新股消息》再鼎医药 (09688.HK):未有扭亏时间表 两产品注册待审批
再鼎医药(09688.HK)首席财务官曹基哲表示,公司目前虽仍然录得亏损,亦未有扭亏时间表,但强调除已商业化的Zejula及Optune外,产品线中有14个项目处於临床阶段,涵盖肿瘤、抗感染及自体免疫性疾病领域,当中2个项目已提交中国新药注册申请,待通过审批後可开始销售。
他透露,来港上市主要是由於见到不少发展机会,期望筹集资金推动公司增长,同时认为香港金融市场对发展中的创新公司友好,亦可更接近亚太区投资者,未来会继续借助两地上市地位,接触全球资本市场。
集资所得约25%预期将用於探索新的全球授权及合作机会,他表示疫情限制出行,对寻找新机会有影响,将加强内部研发能力,并会与其他药企合作增强产品线。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.